Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

1 May 2022

Abstract excerpt

PURPOSE Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate. In these cancers, BRCA1/ 2 alterations and genomic scar signatures are useful indicators for assessing HRD. However, alterations in other homologous recombination repair (HRR)-related genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Genetic factors in colorectal cancer
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35613413
DOI: 10.1200/po.22.00085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesPMID 35613413Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity Read ↗

Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair–associated gene alterations in solid tumors from a large Asian cohortSemantic proximity Read ↗

Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.Semantic proximity Read ↗

Biomarkers for Homologous Recombination Deficiency in CancerSemantic proximity Read ↗

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairSemantic proximity Read ↗

Pan-cancer landscape of homologous recombination deficiency.Semantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Pan-cancer landscape of homologous recombination deficiencySemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer TypesSemantic proximity Read ↗

Genomic Determinants of Homologous Recombination Deficiency across Human CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.